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A RANDOMIZED STUDY OF 
THE INFLUENCE OF 
PERFUSION TECHNIQUE 
AND PH MANAGEMENT 
STRATEGY IN 316 PATIENTS 
UNDERGOING CORONARY 
ARTERY BYPASS SURGERY 
I. Mortality and 
cardiovascular morbidity 
The impact of perfusion technique and mode of pH management during 
cardiopulmonary bypass has not been well characterized with respect to 
postoperative cardiovascular outcome. Methods: This double-blind, random- 
ized study comparing outcomes after alpha-stat or pH-stat management and 
pulsatile or nonpulsatile perfusion during moderate hypothermic ardiopul- 
monary bypass was undertaken in 316 patients undergoing coronary artery 
bypass operations. Results: Cardiovascular morbidity and mortality were not 
affected by pH management, and the incidence of stroke (2.5%) did not differ 
between groups. Overall in-hospital mortality was 2.8%, eight of the nine 
deaths occurring in the nonpulsatile group (5.1% versus 0.6%; p = 0.018). The 
incidence of myocardial infarction was 5.7% in the nonpulsatile group and 
0.6% in the pulsatile group (p = 0.010), and use of intraaortic balloon 
pulsation was significantly more common in the nonpulsatile group (7.0% 
versus 1.9%; p = 0.029). The overall percentage of patients having major 
complications was also significantly higher in the nonpulsatile group (15.2% 
versus 5.7%; p = 0.006). Duration of cardiopulmonary bypass, age, and use of 
nonpulsatile perfusion all correlated significantly with adverse outcome. 
Conclusions: Use of pulsatile perfusion during cardiopulmonary bypass was 
associated with decreased incidences of myocardial infarction, death, and 
major complications. (J TnORAC CARDIOVASC SURG 1995;110:340-8) 
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O Ptimal perfusion characteristics during cardio- pulmonary bypass (CPB) remain controver- 
sial. 1'2 The use of pulsatile perfusion has been 
variously demonstrated to improve myocardial per- 
fusion,3, 4 oxygenation,4-6 compliance, and indices of 
contractility,7, 8 as well as to lower plasma catechol- 
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amine levels, 9' 10 renin activity, 11 angiotensin, aldo- 
sterone, 12 and lactate 13 levels, and to provide better 
preservation of pituitary responsiveness. 14' 15 
Many clinical studies have also demonstrated 
improved myocardial function and lower morbidity 
and mortality after pulsatile compared with nonpul- 
satile perfusion during CPB. 9' 16-19 In contradistinc- 
tion, however, a seemingly equal number of clinical 
studies have been unable to detect benefit associ- 
ated with pulsatile perfusion. 2°-26 
Ideal pH management during moderate hypo- 
thermia for CPB has also been the subject of 
contention. Several studies have assessed the influ- 
ence of pH management on brain and heart func- 
tion, and most have demonstrated relative improve- 
ments with alpha-stat in comparison with pH-stat 
management. 27-29 Some animal studies have also 
shown improved myocardial performance and an 
elevated fibrillation threshold with alpha-stat man- 
agement,27, 2s30, 31 whereas others have been un- 
able to detect differences in the functional capacity 
of the myocardium whether the blood peffusate was 
controlled by means of either alpha-stat or pH-stat 
management strategies. 32 
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Prospective, randomized outcome studies assess- 
ing the differential impact of perfusion technique or 
pH management s rategy on mortality and cardio- 
vascular morbidity have been conducted. However, 
few have used sufficiently large sample sizes to 
demonstrate possible outcome benefit for such low 
base rate events as death and myocardial infarction 
(MI). In most cardiac centers, use of nonpulsatile 
perfusion during CPB continues to be routine, al- 
though use of alpha-stat pH management has been 
increasing over the past decade. We therefore un- 
dertook a prospective, randomized, double-blind 
study in 316 patients undergoing coronary artery 
bypass (CAB) operations to assess differences in 
clinical outcome after use of pulsatile or nonpulsa- 
tile CPB and alpha-stat or pH-stat pH management 
strategies. 
Methods 
This prospective, double-blind, clinical trial, random- 
ized with respect to pH management and perfusion tech- 
nique, was conducted as a part of a study assessing 
neurologic and cognitive outcomes in patients having 
cardiac operations) 3 
Study population. After institutional review board ap- 
proval and written informed patient consent were ob- 
tained, 316 :patients undergoing hypothermic CPB for 
CAB (excluding concomitant open chamber procedures) 
were enrolled in this study. To account for differences in 
surgical technique, randomization was stratified by sur- 
geon (four surgeons) and patients were randomly assigned 
to undergo either pulsatile or nonpulsatile perfusion and 
alpha-stat or pH-stat pH management. 
Outcome measures. Each patient was assessed before 
and after the operation by a blinded research nurse, while 
an independent s udy technician obtained intraoperative 
hemodynamic data. Mortality and major complications, 
including MI, cerebrovascular ccident (CVA), arrhyth- 
mia, use of an intraaortic balloon pump (IABP), and renal 
impairment, were recorded before the operation for each 
patient. Arrhythmia was defined as onset of atrial or 
ventricular arrhythmias necessitating cardioversion or in- 
stitution of specific antiarrhythmic therapy in the postop- 
erative period. CVA was diagnosed on the basis of clinical 
presentation and either confirmatory brain imaging or 
postmortem evidence of cerebral infarction. MI was diag- 
nosed on the basis of development ofnew Q waves on the 
electrocardiogram nd an elevation of creatinine kinase 
myocardial band levels greater than 10% of total creatine 
kinase. MI data do not include patients dying during the 
operation, in whom such data could not be obtained, 
although these latter patients were included in mortality 
statistics. IABP use was defined as successful insertion of 
the IABP. Renal impairment was defined as elevations 
of creatinine concentration 50% above the upper limit of 
laboratory reference normal values. 
CPB. Routine monitoring, including radial and pulmo- 
nary artery cannulation, and high-dose opioid anesthesia, 
supplemented asnecessary with volatile anesthetics, were 
used similarly in all groups. After sternotomy and hepa- 
rinization, moderate systemic hypothermia (nasopharyn- 
geal temperature 26 ° to 28 ° C) with a hollow-fiber mem- 
brane oxygenator (Cobe CML, Cobe Stockert Inc., 
Lakewood, Colo.; Terumo Capiox E, Terumo Corp., 
Tokyo, Japan) having a 40 /~m arterial line filter and 
nonocclusive roller pump, was used for CPB in all pa- 
tients. Flows of 2.0 to 2.5 L. rain -1 ,m -2 were used. 
Crystalloid cardioplegia was used by two surgeons, the 
other two used a 4:1 blood/crystalloid cardioplegic mix- 
ture, and all surgeons used topical cooling with saline 
slush. Ventricular venting was either through the ascend- 
ing aorta or the pulmonary vein. After completion of all 
distal coronary anastomoses, the crossclamp was released, 
rewarming commenced, and proximal graft anastomoses 
performed by means of side-clamping of the aorta. 
In the pulsatile group a pump flow interrupter (Pul- 
satile Flow Controller II, Cobe Stockert Inc.), initially 
set at rate of 65 cps with an ejection time of 65% of 
cycle time, was used from placement of the aortic 
crossclamp until commencement of ventricular ejection 
after rewarming. Analog displays of pulse pressure and 
mean arterial pressure were recorded continuously 
and analyzed specifically after 10, 30, and 60 minutes of 
hypothermic CPB, at commencement of rewarming, 
and after rewarming was completed (i.e., rectal temper- 
ature at or above 34 ° C). Hemodynamic data during 
hypothermia re reported as the means of all specific 
time point values during stable hypothermia. Values for 
normothermia were based on those obtained after 
completion of rewarming. 
Arterial blood gas analysis was performed with a Radi- 
ometer ABL2 analyzer (Radiometer Als, Copenhagen, 
Denmark). For alpha-stat management during CPB, arte- 
rial blood gas was measured at 37 ° C and carbon dioxide 
was adjusted to produce an arterial carbon dioxide tension 
of 40 mm Hg and an arterial pH of 7.4. For pH-stat 
management, arterial blood gas was measured at 37°C 
and corrected to the patient's nasopharyngeal tempera- 
ture with exogenous carbon dioxide adjusted to maintain 
a temperature-corrected arterial carbon dioxide tension of 
40 mm Hg and a temperature-corrected arterial pH of 7.4. 
During CPB, intermittent blood gas analyses, based on 
samples drawn at intervals corresponding to the specific 
time points for hemodynamic measurements, were used to 
maintain either temperature corrected (pH-stat manage- 
ment) or non-temperature corrected (alpha-stat manage- 
ment) arterial pH 7.4 and arterial carbon dioxide tension 
40 mm Hg. Simultaneously with arterial blood gas sam- 
pling, blood was obtained for glucose and hemoglobin 
measurements. 
Statistical analysis. Log-linear model analysis was first 
performed to ensure that no interaction existed between 
pH management, perfusion technique, and outcome 
events. Outcome events were compared between treat- 
ment groups by the X 2 test. Fisher's two-tailed exact est 
was used if the expected cell sizes were small. Demo- 
graphic characteristics were assessed similarly for cate- 
goric variables. Two-way factorial analysis of variance was 
used to examine continuous variables and to confirm that 
pH management did not interact with perfusion tech- 
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Table I. CAB group demographics (numbers of patients, or mean +_ standard deviation) 
Alpha-star pH-stat 
Pulsatile Nonpulsatile Pulsatile Nonpulsatile CAB total 
(n = 79) (n = 79) (n = 79) (n = 79) (n = 316) 
Age (yr) 60.9 + 8.7 61.2 - 7.8 60.2 -+ 8.5 61.4 + 8.4 60.9 + 8.3 
Gender (M/F) 66/13 65/14 70/9 63/16 264/52 
CVA/TIA 8 11 9 4 32 (10%) 
DM 20 17 8 13 58 (18%) 
MI <1/12 9 9 9 6 33 (10%) 
Prey. CAB 4 9 8 7 28 (9%) 
LVEF <50% 23 23 29 22 97 (31%) 
LVEF <35% 5 6 4 2 17 (5%) 
CVA/TIA, History of cerebrovascular ccident or transient ischemic attack; DM, diabetes mellitus; MI <1//2, myocardial infarction in previous month; Prec. 
CAB, previous coronary bypass urgery; LVEF <50%, LVEF <35% patients with left ventricular ejection fraction less than 50% or 35%. 
Table II. Distribution and intraoperative characteristics by CAB group (numbers of patients, or mean +_ 
standard deviation) 
Alpha-stat pH-stat 
PulsatiIe Nonpulsatile Pulsatile Nonpulsatile CAB total 
(n = 79) (n = 79) (n = 79) (n = 79) (n = 316) 
Surgeon 1 22 24 24 24 94 
Surgeon 2 26 25 22 26 99 
Surgeon 3 5 6 6 4 21 
Surgeon 4 26 24 27 25 102 
NPT (° C) 28.5 + 2.1 28.5 + 1.2 28.5 + 2.0 28.2 _+ 1.2 28.4 _+ 1.7 
Hgb (gm/L) 78.4 _+ 18.4 78.9 _+ 11.5 81.5 _+ 14.5 78.4 _+ 12.3 79.3 -+ 14 
Glu (mmol/dl) 10.6 -+ 3.5 11.3 -+ 3.0 10.4 _+ 3.1 10.4 -+ 3.0 10.7 + 3.1 
CAB 2.9 _+ 0.6 2.9 _+ 0.8 3.0 +_ 0.8 3.0 +- 0.8 3.0 -+ 0.7 
CAB >4 10 16 22 17 65 (21%) 
AoXC (min) 43.9 _+ 17.4 44.1 +_ 18.1 47.8 _+ 17.2 46.9 _+ 15.5 45.7 +_ 17 
CPB (rain) 92.1 +_ 29.1 95.1 _+ 29.1 98.5 + 36.7 98.6 _+ 32.6 96.1 _+ 32 
OR (min) 271 -4- 48 280 _+ 76 279 _+ 59 282 _+ 57 278 _+ 61 
Hosp (days) 13.4 _+ 10.8 12.2 _+ 5.1 14.8 _+ 24.8 12.9 _+ 11.1 13.3 + 15 
Surgeon N,, Number of patients in each group operated on by individual surgeon; NPT, mean nasopharyngeal temperature during hypothermic CPB; Hgb, 
lowest mean hemoglobin concentration during hypothermic CPB; Glu, highest mean glucose values during hypothermic CPB; CAB, mean umber of coronary 
bypass grafts; CAB >4, patients having four or more coronary bypass grafts; AoXC, aortic crossclamp time; CPB, duration of cardiopulmonary bypass; OR, 
duration of operation; Hosp, operation to discharge time with in-hospital deaths excluded. 
nique. No adjustments were made for multiple compari- 
sons. Logistic regression analysis was applied to examine 
potential risk factors for adverse outcomes. 
Results 
Characteristics of patients. Demographic and 
clinical characteristics of the 316 patients in the 
study are shown in Table I. Table II shows 
distribution of patients into study group according 
to surgeon and intraoperative and postoperative 
values. No significant differences were identified 
between groups in any parameters including de- 
mographics, CPB duration, ischemic time, ventric- 
ular function, or numbers of coronary vessels 
bypassed. 
Alpha-stat versus pH-stat groups. For pH man- 
agement groups, intended treatments during CPB 
were achieved such that there was a significant 
difference in arterial pH of 0.11 __ 0.18 pH units and 
of arterial carbon dioxide tension of 20.6 ± 7.8 mm 
Hg between alpha-stat and pH-stat groups during 
hypothermic CPB (Table III). 
Pulsatile versus nonpulsatile groups. During hy- 
pothermia, mean arterial pressure was similar be- 
tween the two groups. Pulsatile perfusion was asso- 
ciated with a significantly greater pulse pressure, 
averaging 14.8 ± 6.7 mm Hg higher during hypo- 
thermic CPB and 6.8 ± 14 mm Hg higher during 
normothermic CPB than in the nonpulsatile group 
(see Table III). During CPB there were no differ- 
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Table III. Perfusion characteristics by CAB group (mean +_ standard eviation) 
Alpha-stat pH-stat 
CAB total PuIsatile Nonpulsatile Pulsatile Nonpulsatile 
(n = 316) (n : 79) (n = 79) (n = 79) (n = 79) 
PP-C (ram Hg) 16.9 _+ 6.1" 1.8 _+ 2.4 15.5 _+ 6.8* 1.6 ± 2.4 
PP-NT (mm Hg) 11.1 ± 9.9* 5.5 ± 12.6 12.0 ± 9.3* 4.1 ± 7.3 
MABP (mm Hg) 57.9 ± 12.3 61.0 ± 11.3 57.2 ± 10.1 57.6 ± 11.9 
pHa'~ 7.42 ± 0.18:) 7.43 _+ 0.12:) 7.54 ± 0.13 7.54 ± 0.06 
Paco2 (ram Hg)'~ 38.i ± 4.1:) 37.5 ± 4.1:) 57.5 ± 6.9 59.3 ± 6.4 
PP-C, Mean pulse pressure during hypothermic CPB; PP-NT, pulse pressure during normothermic CPB; MABP, lowest mean arterial blood pressure during 
hypothermic CPB; pHa, arterial pH; Paco2, arterial carbon dioxide tension. 
*p < 0.001 versus nonpulsatile. 
?Mean of all values as measured at 37 ° C during hypothermic CPB. 
:~p = 0.00i versus pH-stat. 
ences in urine output between pulsatile or nonpul- 
satile groups (367 __ 346 ml versus 378 _+ 358 ml, 
respectively), consistent with what we had observed 
in a subset of 100 of these patients in whom frac- 
tional excretion of sodium and potassium, as well as 
renal failure index, did not differ between perfusion 
groups. 34 
Surgical morbidity and mortality. Data on car- 
diovascular and other major complications were 
assessed and patients with major complications are 
listed individually in Table IV. There was no differ- 
ence in cardiovascular outcomes related to pH 
management (e.g., mortality 3/158 versus 6/158; MI 
3/158 versus 7/158; alpha-stat versus pH-stat, respec- 
tively). A significant difference in cardiovascular 
outcomes was observed that strongly favored pulsa- 
tile perfusion, however. In the nonpulsatile group 
there were significantly higher rates of mortality 
(8/158 versus 1/158, p = 0.018), MI (9/158 versus 
1/158, p = 0.010), and IABP use (11/158 versus 
3/158, p = 0.029) than in the pulsatile group. These 
factors contributed toward a decreased overall inci- 
dence of major complications in the pulsatile group 
(24/158 versus 9/158, p = 0.006). The percentage of 
patients who died or had major complications, bro- 
ken down by perfusion technique, is presented in 
Fig. 1. TO assess the effect of patients with compli- 
cations disproportionately influencing morbidity 
data, we undertook a repeat analysis of complica- 
tions involving only surviving patients. A trend (/9 = 
0.062) for fewer MIs in the pulsatile group persisted 
(1/157 versus 6/150, respectively). Of the patients 
who died, three died during the operation of cardiac 
failure, three died within 14 days after the operation 
of MI with irreversible low output state, one of 
whom also had a CVA, two died within 5 days of a 
CVA with irreversible brain injury, and one patient 
died 4 months after the operation of multisystem 
failure. 
Cardiovascular risk factors. Univariate logistic 
regression was used to determine the relationship 
between the presence of adverse outcomes, defined 
as death, MI, arrhythmia, or IABP insertion, and 
potential risk factors, identified as insulin-depen- 
dent diabetes mellitus, MI within the previous 
month, gender, left ventricular ejection fraction less 
than 0.5, left ventricular ejection fraction less than 
0.35, number of coronary arteries grafted, perfusion 
technique, pH management s rategy, cardioplegia 
type (blood or crystalloid), cardioplegia volume, 
age, duration of crossclamping, and duration of 
CPB. Significant correlations were found for use of 
nonpulsatile perfusion (p = 0.0082), age (p = 
0.0211), and CPB duration (p = 0.0006). When 
examined multivariately, these factors remained sig- 
nificant risk factors (p = 0.0106,p = 0.0223, andp = 
0.0003, respectively) for adverse outcome. The other 
factors listed did not correlate with adverse out- 
come. Although cardioplegia type did not correlate 
with adverse outcome, surgeons using crystalloid 
eardioplegia completed more CAB grafts (3.1 _+ 0.8 
versus 2.8 _ 0.6, respectively; p = 0.001) with 
shorter crossclamp times (41.5 _ 14.1 minutes ver- 
sus 59.3 ± 13.3 minutes, respectively; p < 0.001) 
than those using blood cardioplegia. 
Discussion 
The current study demonstrated significantly 
lower incidences of mortality and cardiovascular 
morbidity in patients undergoing pulsatile CPB but 
no detectable influence of pH management strategy 
on these outcome variables. The overall incidences 
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Table IV. Individual mortality and major morbidity for pulsatile versus nonpulsatile CPB 
Patient Death MI Arrhythmia CVA IABP Renal 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Nonpulsatile CPB (n = 158) 
X X 
X 
X 
X 
X 
X 
X 
X 
X 
Pulsatile CPB (n = 158) 
X 
X 
X 
X 
X 
X X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1 X X 
2 X 
3 X 
4 X X 
5 X X 
6 X X X 
7 
8 X 
9 X X 
p = 0.006* p = 0.018 p = 0.010 p = 0.157 p = 1.0 p = 0.029 p = 0.371 
The incidence of death, myocardial infarction (MI), postoperative arrhythmia necessitating treatment, cerebrovascular accident (CVA), use of intraaortic 
balloon pump (IABP), and renal insufficiency for those patients undergoing pulsatile versus nonpulsatile perfusion during cardiopulmonary bypass (CPB). The 
p values comparing incidences of complications between the two groups are along the bottom of the table. 
*This value refers to the relative incidences of any complications in the two groups. 
of MI (3.2%), IABP use (4.4%), CVA (2.5%), and 
mortality (2.8%) reported in the current study are 
consistent with results reported in the literature. In 
a recent survey of 1513 patients undergoing CAB, 
MI occurred in 5.5%, 4.7% required IABP, CVA 
occurred in 2.8%, and overall mortality rate was 
3.1%. 35 
pit management. Two divergent strategies for 
pH management have generally been used clinically: 
(1) pH-stat--addition of exogenous carbon dioxide 
to the oxygenator to achieve a temperature-cor- 
rected arterial pH of 7.4 and an arterial carbon 
dioxide tension of 40 mm Hg; (2) alpha-stat-- 
during which total carbon dioxide is kept constant 
and pH and arterial carbon dioxide tension vary with 
body temperature. 29 
In the current study, we did not find any influence 
of mode of pH management on cardiovascular 
morbidity or mortality. This observation likely re- 
flects both the relatively insensitive clinical end 
points used (e.g., MI and IABP use) and, more 
fundamentally, the fact that he heart is not perfused 
and is effectively excluded from the systemic circu- 
lation (and thus largely uninfluenced by mode of pH 
management) during hypothermia by virtue of the 
aortic crossclamp. Rewarming, and thus conver- 
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NON PULSATILE (n=158) 
PULSATILE (n= 158) 
0 
Z 
Cm 
5 
Z 
N 
7 
6 
5 
4 
3 
2 
1 
0 
p=0.157 
p=0.01 N 
/ 
DEATH MI ARRHYTHMIA 
~=I.0 
OvA 
p=0.029 
IABP 
Fig. 1. The incidence of death, MI, postoperative arrhythmia necessitating treatment, CVA, and use of 
IABP for those patients undergoing pulsatile versus nonpulsatile perfusion during CPB. 
gence of both alpha-stat and pH-stat strategies, 
generally commences during performance of the last 
of the distal coronary anastomoses, while the heart 
is still isolated from systemic perfusion. 
Pulsatile perfusion. The current study docu- 
mented markedly lower mortality in patients under- 
going pulsatile CPB. Although nonfatal adverse 
outcomes (e.g., MI, IABP) and mortality over- 
lapped, analysis of data from surviving patients till 
demonstrated a trend for a higher incidence of MI 
in the nonpulsatile group (6/150 versus 1/157). Rea- 
sons for these differences in outcome remain spec- 
ulative. They are unlikely to reflect differences in 
surgical technique, because stratification by surgeon 
ensured that the number of patients in both pulsatile 
and nonpulsatile groups was balanced between sur- 
geons. Assignment into pulsatile or nonpulsatile 
groups was also undertaken i a blinded fashion, 
and there was no subsequent crossover during the 
operations. Disproportionate weighting of patients 
at higher risk into one group or the other is thus 
unlikely, although no attempt was made preopera- 
tively to stratify patients into treatment groups 
according to cardiovascular or other risk factors. 
Review of patient characteristics (see Tables I and 
II) confirms the randomization process and does not 
reveal any significant differences inpreoperative risk 
factors. 
To date only two other large-scale studies as ess- 
ing cardiovascular outcomes after pulsatile or non- 
pulsatile CPB have been presented, and they have 
similarly reported salutary effects of pulsatile perfu- 
sion. Significantly decreased mortality rates with 
pulsatile pcrfusion were reported by Taylor and 
associates is in a series of 350 patients with cardiac 
disease randomized to pulsatile or nonpulsatile per- 
fusion; Taylor's group used a roller-pump system 
similar to the one we employed. In that series 
significantly lower requirements for postoperative 
circulatory support modalities were demonstrated, 
and mortality from low-output cardiogenic shock 
was significantly decreased from 6.3% to 1.1%. 
More recently, Minami and coworkers ~9 reported 
that in a retrospective comparison of 175 patients 
undergoing CPB for greater than 120 minutes, pul- 
satile perfusion decreased the incidence of cardio- 
vascular morbidity, although overall mortality was 
not affected. 
The mechanism responsible for the decreased 
incidence of cardiovascular complications remains 
speculative. However, it is possible that during the 
early reperfusion phase reductions inneurohumoral 
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stress responses and improvements in myocardial 
contractility and subendocardial blood flow are con- 
tributory.3, 4  7-10 
In fibrillating hearts, increased myocardial oxygen 
and lactate extraction, improved subendocardial 
blood flow, 3' 4, 36-38 and increased iastolic compli- 
ance 4 have been observed with pulsatile perfusion. 
Clinical studies also demonstrated increased ejec- 
tion fractions, lower incidences of MI, and increased 
coronary graft blood flow. 16' 17, 39 In the presence of 
acute coronary stenoses, pulsatile perfusion is asso- 
ciated with higher oxygen tension, lower tissue car- 
bon dioxide tension, and greater subendocardial 
blood flow. s' 38 A recent study of dogs with coronary 
artery ligation and profound heart failure has con- 
firmed increased coronary blood flow and an im- 
proved ratio of diastolic time index/tension time 
index with pulsatile as compared with nonpulsa- 
tile perfusion for left ventricular bypass. 4° Lower 
levels of thromboxane and increased concentra- 
tions of prostacyclin, changes favoring coronary 
vasodilatation and augmented myocardial blood 
flow, have also been demonstrated with pulsatile 
perfusion. 41 
However, other studies have been unable to dem- 
onstrate any significant influence of perfusion tech- 
nique. 21-26 Overall, benefit does appear to be more 
likely at lower rather than higher perfusion flow 
rates, 2in fibrillating rather than beating hearts, 3'4, 6 
and in the presence of global ischemia,  ventricular 
hypertrophy, 7 and acute s rather than chronic 42 isch- 
emia. 
Whether any of these experimental conditions are 
directly comparable to the clinical situation encoun- 
tered during CAB operations, given that the heart is 
isolated and nonperfused for over half the duration 
of CPB, is unclear. It is apparent hat pulsatile 
perfusion can significantly increase subendocar- 
dial myocardial perfusion during ventricular fi- 
brillation, particularly in the presence of coronary 
stenoses. It can also enhance subsequent load- 
dependent performance. In clinical practice the 
heart is often nonbeating or fibrillating for a 
variable period after removal of the aortic cross- 
clamp, during which time the proximal graft anas- 
tomoses are being made. During this critical 
postischemic reperfusion phase, it may be that 
improved subendocardial perfusion, in conjunc- 
tion with increased prostacyclin and decreased 
catecholamine l vels, may be factors in the ira- 
proved clinical cardiovascular outcomes demon- 
strated with pulsatile flow. 
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